Regen BioPharma Inc (RGBP) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US75886M1027
Regen BioPharma Inc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 236,561.00 USD |
| Operating income | -338,540.00 USD |
| EBIT | -1.12 m USD |
| Net income | -1.27 m USD |
| Diluted EPS – continuing operations | -0.05 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Regen BioPharma Inc
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.
More stocks
- Bespoke Extracts, Inc. (BSPK)
- Cambium Networks Corp (CMBMF)
- SHF Holdings, Inc. (SHFS)
- Cloudweb, Inc. (CLOW)
- Community Redevelopment Inc. (CRDV)
- Vestand Inc. (VSTD)
- 22nd Century Group, Inc. (XXII)
- ScanTech AI Systems Inc. (STAI)
- LIPELLA PHARMACEUTICALS INC. (LIPO)
- Sleep Number Corp (SNBRQ)
- ADVENT TECHNOLOGIES HOLDINGS, INC. (ADNH)
- Banzai International, Inc. (PARA)
Not investment advice. All data without warranty, price as of 16.11.2026. Details in the risk notice.